Celluminova develops GlioStem®, a patented biomarker that utilizes polymer technology for the near-instant detection and visualization of glioma stem cells in brain tumors. This tool addresses the lack of existing products targeting stem-like cells, aiming to enhance surgical outcomes and potentially improve patient survival rates.
Funding
$405.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting glioma stem cells in brain tumors are inadequate, leading to incomplete tumor removal during surgery and potentially impacting patient survival rates. There is a lack of readily available tools that specifically target and visualize these stem-like cells in real-time during surgical procedures.
Solution
Celluminova's GlioStem® is a patented biomarker that enables near-instant detection and visualization of glioma stem cells within brain tumors. Utilizing polymer technology, GlioStem® aims to improve surgical outcomes by allowing surgeons to more effectively identify and remove all tumor tissue, including stem-like cells, during surgery. This enhanced precision in tumor removal has the potential to increase patient survival rates. GlioStem® represents a new generation of biomarkers designed to address the unmet need for targeted stem cell detection in brain tumors.
Target Audience
The primary target audience includes surgeons and medical professionals involved in the treatment of brain tumors, as well as researchers focused on stem cell research and cancer stem cells.
Features
- Polymer-based technology for rapid detection of glioma stem cells.
- Biomarker designed for near-instant visualization of stem-like cells in brain tumors.
- Specifically targets stem-like cells, which are often missed by conventional methods.